Abstract:Graphical and Lay Summary In this work, the authors present the design of improved Rep/Cap and Helper plasmids for rAAV2/8 production, (i) a Rep/Cap expression vector harboring independently controllable rep and cap genes and (ii) an improved Helper plasmid harboring E4 gene deletion variants. The data show that configuring and controlling the expression of the different AAV genetic elements contribute toward high rAAV production and product quality. Recombinant adeno‐associated virus (rAAV) is the leading vector for the delivery of gene therapies. However, low viral genome (VG) titers are common and the proportion of "full" capsids containing the therapeutic gene payload can be highly variable. The coordinated molecular design of plasmids encoding viral components and Helper functions remains a major challenge for rAAV manufacturing. Here we present the design of improved Rep/Cap and Helper plasmids for rAAV2/8 production, (i) a Rep/Cap expression vector harboring independently controllable rep and cap genes and (ii) an improved Helper plasmid harboring E4 gene deletion variants. First, an optimized Rep/Cap vector utilized a truncated p5 promoter, a p5 cis‐regulatory element at the 3′ end in combination with a heterologous promoter to drive Cap expression and an additional copy of the rep52/40 gene to overexpress short Rep proteins. We demonstrate that Rep78 is essential for efficient rAAV2/8 production in HEK293 cells, and a higher ratio of short Rep to long Rep proteins enhances genome packaging. Second, we identified regulators and open reading frames within the Helper plasmid that contribute to increased rAAV2/8 production. While L4‐33k/22k is integral to optimal production, the use of E4orf6–6/7 subset significantly enhanced VG titer. Together, an optimal combination of engineered Rep/Cap and Helper plasmid variants increased VG titer by 3.1‐fold. This study demonstrates that configuring and controlling the expression of the different AAV genetic elements contributes toward high rAAV production and product quality (full/empty capsid ratio).

AAV Production Everywhere: A Simple, Fast, and Reliable Protocol for In‐house AAV Vector Production Based on Chloroform Extraction

Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing.

A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform

A Rapid Method for Producing Adeno-Associated Viral Vectors Suitable for Transducing Rodent Neurons and

High-Level rAAV Vector Production by rAdV-Mediated Amplification of Small Amounts of Input Vector

Process Improvement of Adeno-Associated Virus Production

Production of High-Yield Adeno Associated Vector Batches Using HEK293 Suspension Cells

Suspension Culture Production and Purification of Adeno-Associated Virus by Iodixanol Density Gradient Centrifugation for In Vivo Applications

Advanced biomanufacturing and evaluation of adeno-associated virus

High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells

High‐yield recombinant adeno‐associated viral vector production by multivariate optimization of bioprocess and transfection conditions

A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors.

Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells

Comprehensive Comparison of AAV Purification Methods: Iodixanol Gradient Centrifugation Vs. Immuno-Affinity Chromatography.

A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy.

Enhancing the production of recombinant adeno-associated virus in synthetic cell lines through systematic characterization

Producing high-quantity and high-quality recombinant adeno-associated virus by low-cis triple transfection

Molecular design of controllable recombinant adeno‐associated virus (AAV) expression systems for enhanced vector production

Process Optimization for the Rapid Production of Adenoviral Vectors for Clinical Trials in a Disposable Bioreactor System.

Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination

Unravelling the essential elements for recombinant adeno-associated virus (rAAV) production in animal cell-based platforms